[go: up one dir, main page]

GB0811091D0 - CYP26 Inhibitors - Google Patents

CYP26 Inhibitors

Info

Publication number
GB0811091D0
GB0811091D0 GBGB0811091.8A GB0811091A GB0811091D0 GB 0811091 D0 GB0811091 D0 GB 0811091D0 GB 0811091 A GB0811091 A GB 0811091A GB 0811091 D0 GB0811091 D0 GB 0811091D0
Authority
GB
United Kingdom
Prior art keywords
cyp26 inhibitors
cyp26
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0811091.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to GBGB0811091.8A priority Critical patent/GB0811091D0/en
Publication of GB0811091D0 publication Critical patent/GB0811091D0/en
Priority to PCT/GB2009/001533 priority patent/WO2009153566A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0811091.8A 2008-06-17 2008-06-17 CYP26 Inhibitors Ceased GB0811091D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0811091.8A GB0811091D0 (en) 2008-06-17 2008-06-17 CYP26 Inhibitors
PCT/GB2009/001533 WO2009153566A1 (fr) 2008-06-17 2009-06-17 Inhibiteurs de cyp26

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0811091.8A GB0811091D0 (en) 2008-06-17 2008-06-17 CYP26 Inhibitors

Publications (1)

Publication Number Publication Date
GB0811091D0 true GB0811091D0 (en) 2008-07-23

Family

ID=39672423

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0811091.8A Ceased GB0811091D0 (en) 2008-06-17 2008-06-17 CYP26 Inhibitors

Country Status (2)

Country Link
GB (1) GB0811091D0 (fr)
WO (1) WO2009153566A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6088425B2 (ja) 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
WO2014093960A1 (fr) * 2012-12-16 2014-06-19 Angion Biomedica Corp. Compositions et méthodes de traitement de maladie
ES2886641T3 (es) 2014-08-11 2021-12-20 Angion Biomedica Corp Inhibidores de citocromo P450 y sus usos
RU2692774C2 (ru) 2014-08-29 2019-06-27 Дайсел Корпорэйшн Имидазольное соединение, жидкость для обработки металлической поверхности, способ обработки металлической поверхности и способ изготовления ламината
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188957T3 (es) * 1996-06-27 2003-07-01 Janssen Pharmaceutica Nv N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
MX2008009215A (es) * 2006-01-17 2008-12-10 Barrier Therapeutics Inc Tratamiento de trastornos inflamatorios con compuestos de triazol.

Also Published As

Publication number Publication date
WO2009153566A1 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL211693A0 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201100898B (en) Novel inhibitors
ZA201204104B (en) Prolyl hydroxylase inhibitors
IL238583A0 (en) 2-acylaminopropanol-like as glucosylceramide synthase inhibitors
GB0811091D0 (en) CYP26 Inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
GB0810011D0 (en) 5-Lipoxygenase inhibitors
GB0817429D0 (en) Enzyme inhibitors
GB0714941D0 (en) Inhibitors
GB201019387D0 (en) Inhibitors
GB0812443D0 (en) Enzyme inhibitors
GB0807056D0 (en) Enzyme inhibitors
GB0816125D0 (en) Novel inhibitors
HK1160453A (en) Phosphodiestarase inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0902661D0 (en) Inhibitors
HK1160608A (en) 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
GB0901616D0 (en) Enzyme inhibitors
GB0908068D0 (en) Enzyme inhibitors
PL386893A1 (pl) Inhibitor parafin
GB0721868D0 (en) eNZYME INHIBITORS
GB0706853D0 (en) Enzyme inhibitors
SI2496236T1 (sl) Prolilhidroksilazni inhibitorji

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)